HNSA — Hansa Biopharma AB Share Price
Last trade - 00:00- SEK4.77bn
- SEK4.38bn
- SEK222.27m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 9.17 | ||
| Price to Sales | 15.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -63.1% | ||
| Return on Equity | n/a | ||
| Operating Margin | -204.83% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 33.88 | 154.53 | 134.09 | 171.32 | 222.26 | 1,297.41 | 353.77 | 105.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
Directors
- Peter Nicklin NEC (62)
- Hitto Kaufmann SVP (55)
- Evan Ballantyne CFO (66)
- Renee Aguiar-Lucander CEO (62)
- Maria Tornsen COO (46)
- Richard Philipson SVP (61)
- Sandra Frithiof CHO (50)
- Natalie Berner IND (36)
- Elisabeth Bjoerk IND (65)
- Brian Gorman SVP (50)
- Shannon Campbell DRC
- Gregory Perry DRC
- Last Annual
- December 31st, 2025
- Last Interim
- September 30th, 2026
- Incorporated
- July 10th, 2007
- Public Since
- October 17th, 2007
- No. of Shareholders
- 21,000
- No. of Employees
- 111
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 101,763,222
- Address
- Scheelevagen 22, LUND, 223 63
- Web
- https://www.hansabiopharma.com/
- Phone
- +46 46165670
- Contact
- Evan Ballantyne
- Auditors
- KPMG AB
Latest News for HNSA
Upcoming Events for HNSA
Q4 2026 Hansa Biopharma AB Earnings Release
Q1 2027 Hansa Biopharma AB Earnings Release
Similar to HNSA
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
Alzinova AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 11:02 UTC, shares in Hansa Biopharma AB are trading at SEK46.84. This share price information is delayed by 15 minutes.
Shares in Hansa Biopharma AB last closed at SEK46.84 and the price had moved by +73.74% over the past 365 days. In terms of relative price strength the Hansa Biopharma AB share price has outperformed the FTSE Global All Cap Index by +50.42% over the past year.
The overall consensus recommendation for Hansa Biopharma AB is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreHansa Biopharma AB does not currently pay a dividend.
Hansa Biopharma AB does not currently pay a dividend.
Hansa Biopharma AB does not currently pay a dividend.
To buy shares in Hansa Biopharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK46.84, shares in Hansa Biopharma AB had a market capitalisation of SEK4.77bn.
Here are the trading details for Hansa Biopharma AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: HNSA
Based on an overall assessment of its quality, value and momentum Hansa Biopharma AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Hansa Biopharma AB is SEK68.63. That is 46.52% above the last closing price of SEK46.84.
Analysts covering Hansa Biopharma AB currently have a consensus Earnings Per Share (EPS) forecast of SEK1.09 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hansa Biopharma AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +45.12%.
As of the last closing price of SEK46.84, shares in Hansa Biopharma AB were trading +35.04% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hansa Biopharma AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK46.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hansa Biopharma AB's management team is headed by:
- Peter Nicklin - NEC
- Hitto Kaufmann - SVP
- Evan Ballantyne - CFO
- Renee Aguiar-Lucander - CEO
- Maria Tornsen - COO
- Richard Philipson - SVP
- Sandra Frithiof - CHO
- Natalie Berner - IND
- Elisabeth Bjoerk - IND
- Brian Gorman - SVP
- Shannon Campbell - DRC
- Gregory Perry - DRC